BloFin Futures to List AIGENSYNUSDT: 0 Maker Fees & 50% off Taker Fees!

April 29, 2026 at 10:02 PM
Dear BloFin users,
 

We are pleased to announce that the USDT-Margined perpetual contract for AIGENSYNUSDT will be listed at 14:30 UTC on Apr 29, 2026

The updates will cover both the web and app interfaces. The details are as follows:

  • AIGENSYNUSDT Perpetual:
 
Feature
Details
Underlying Asset
AIGENSYN (Gensyn) 
Settlement Asset
USDT
Project Info
Gensyn is a decentralized machine intelligence protocol designed to unify data and compute into a single, open network.
Contract Size
100 AIGENSYN
Price Quotation
100 AIGENSYN value calculated in USDT equivalent
Tick Size
0.00001
Leverage
1-20X
Funding Fee Settlement Frequency
Every 4 hours
Trading Hours
24/7

 

🎉Event: Trade AIGENSYNUSDT with 0 Maker Fees & 50% Off Taker Fees
To celebrate the launch of the new trading pair on BloFin Futures, we will offer 0 Maker fees and 50% off Taker fees during the first 48 hours after listing — with Taker fees as low as 0.03%!
 
Please note:
  • The price limit rules of AIGENSYNUSDT perpetual trading are the same as those of other cryptos. Please refer to our trading rules for further details.
  • View the Step-by-Step Guide: How to Trade on BloFin Futures
 
To experience the innovative power of BloFin, please go to the BloFin website or download the App from the Apple App Store and Google Play Store to trade easily on the go.
 
Thank you for your support!
 
BloFin Team
Apr 29, 2026
 
Find us on:
 
BloFin reserves the right, in its sole discretion, to amend or cancel this announcement at any time and for any reason without prior notice.
 
Risk Warning: Digital assets are highly speculative and subject to significant volatility. They may become illiquid at any time, and investors could lose the entire value of their investment. Before trading any digital asset, you should conduct your own research and assess your risk tolerance. BloFin is not liable for any losses you may incur from trading digital assets. This material should not be construed as financial advice. For more information, view our Terms of Use and Risk Warning.
 
Was this article helpful?